

**INVITATION TO 1-DAY-SYMPOSIUM**

# The imminent danger of Lp(a): Time to face the challenge



**FRIDAY, MAY 24, 2019 | 09:00 - 17:30 HRS**

**BONBONNIÈRE – MAASTRICHT, THE NETHERLANDS**

# INVITATION

**FRIDAY, MAY 24, 2019 | 09:00–17:30 HRS | MAASTRICHT, THE NETHERLANDS**

**Dear colleague,**

As a clinician with an interest in cardiovascular disease and atherosclerosis, you are cordially invited to participate in an EAS-endorsed satellite symposium to be held prior to the 87th EAS congress.

## *“The imminent danger of Lp(a): Time to face the challenge”*

Elevated Lipoprotein(a) mediates myocardial infarction, stroke, and peripheral arterial disease. Lp(a) is considered as a causal, genetically determined risk factor for atherosclerosis and CVD. Ever since the strong association between elevated levels of Lp(a) and an increased risk for CVD was recognized, interest in the therapeutic modulation of Lp(a) levels has increased. Detailed studies of the metabolism of Lp(a) are required to develop selective and potent therapies to lower Lp(a).

This symposium is fully dedicated to explore the emerging role of Lp(a) in the development of cardiovascular disease and as a target for current and future therapies.

Leading experts in Lp(a) research will share their knowledge and research results into this important risk factor for atherosclerosis.

The symposium is an initiative of the Dutch Atherosclerosis Society (DAS) in collaboration with the Physicians' Academy for Cardiovascular Education foundation (PACE-CME).

The agenda consists of 4 key sessions divided in:

- Lp(a) - Pathophysiology
- Lp(a) - Epidemio-Genetics
- Lab challenges - Lp(a)
- Therapy targeting Lp(a)

The sessions are a mix of state of the art presentations by international experts and contributions of young investigators. During breaks there will be poster presentations.

We look forward to your participation in this interesting symposium and invite you to share this important event with us!

Co-chairmen and programme directors of the symposium:

**Prof. Erik Stroes, MD** – *Amsterdam University Medical Centers, The Netherlands; Chairman Dutch Atherosclerosis Society*

**Prof. Pia Kamstrup, MD** – *Copenhagen University Hospital, Denmark*

**Prof. Sam Tsimikas, MD** – *University of California San Diego, CA, USA*

# Agenda

**FRIDAY, MAY 24, 2019 | 09:00–17:30 HRS | MAASTRICHT, THE NETHERLANDS**

09:00 – 09:15      **Welcome & Introduction**  
Erik Stroes – Amsterdam, The Netherlands

## **Session 1: Pathophysiology**

09:15 – 09:45      **(Hi)story of Lp(a) into the CV arena**  
Florian Kronenberg – Innsbruck, Austria

09:45 – 10:15      **Lp(a) and calcification in aortic stenosis**  
Kang Zheng – Brigham and Women’s Hospital, Boston, MA, USA  
(also on behalf of Marc Dweck, Edinburgh, United Kingdom)

10:15 – 10:35      **Lp(a) and immune metabolism**  
Jeffrey Kroon – Amsterdam, The Netherlands

10:35 – 11:00      **Coffee break and Posters**

## **Session 2: Epidemio-Genetics**

11:00 – 11:30      **Lp(a) (genetics/plasma) and CV morbidity and mortality**  
Pia Kamstrup – Copenhagen, Denmark

11:30 – 12:00      **Prevalence and relevance of Lp(a) in familial hypercholesterolemia**  
Børge Nordestgaard – Copenhagen, Denmark

12:00 – 12:20      **Lp(a) apheresis and CVD risk (modulation)**  
Elisa Waldmann - Munich, Germany

12:20 – 13:15      **Lunch Break and Posters**

## **Session 3: Lab challenges**

13:15 – 13:45      **Structural determinants of lipoprotein(a) pathogenicity**  
Marlys Koschinsky – London, ONT, Canada

13:45 – 14:15      **Are we ready for prime-time assay standardisation?**  
Santica Marcovina – Seattle, WA, USA

14:15 – 14:35      **LDL vs Lp(a) cholesterol: confounding**  
Calvin Yeang – San Diego, CA, USA

14:35 – 15:00      **Tea Break and Posters**

## **Session 4: Therapy**

15:00 – 15:30      **Estimated impact of Lp(a) modulation on CVD-risk**  
Brian Ference – Cambridge, United Kingdom

15:30 – 16:00      **Lp(a) contribution to PCSK9-ab benefit in ODYSSEY**  
Wouter Jukema – Leiden, The Netherlands

16:00 – 16:45      **Phase II data, followed by NHLBI recommendation**  
Sam Tsimikas – San Diego, CA, USA

16:45 – 17:30      **Reception and Posters**

## **Participation**

This educational program is designed for clinicians and researchers with an interest in Lp(a), atherosclerosis and cardiovascular disease.

## **Meeting venue**

Bonbonnière (a theatre downtown the city of Maastricht)

Address: Achter de Comedie 1, 6211 GZ Maastricht, The Netherlands

## **Registration**

Physicians and scientists who are interested are cordially invited to register for participation. To register for the satellite symposium, please use the following web link:

<http://register.medconinternational.com/SATEAS19>

## **CME accreditation**

CME accreditation is being applied for at The European Board for accreditation in Cardiology (EBAC).

The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other's accreditation systems as substantially equivalent.

## **Meeting logistics**

The programme and logistics in Maastricht are managed by MEDCON International on behalf of PACE-CME. For more information please contact MEDCON International at:

Tel.: +31 (0) 23 5317 357 or e-mail, [info@medconinternational.com](mailto:info@medconinternational.com).

## **Physicians' Academy for Cardiovascular Education (PACE) foundation**

The rationale for establishing the PACE foundation, the Physicians' Academy for Cardiovascular Education foundation comes from the recognition that physician education plays an increasingly important role in our efforts to reduce the burden of cardiovascular disease and diabetes. The goal of PACE is to help physicians assimilate the proven findings of scientific research into the day-to-day practice of clinical medicine, all in the interest of improving outcomes in patients.

## **Mission PACE**

The mission of PACE is to improve the cardiovascular health of patients by providing an international forum for the review, exchange and assimilation of new important data underlying cardiovascular disease and diabetes and accelerate the translation of this information into clinical practice.

## **Funding**

The PACE foundation received funding for this session via unrestricted educational grants from Amgen and Novartis.